Sorafenib Long Term Extension Program
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Acronyms STEP
- Sponsors Bayer
- 12 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Mar 2018 Planned End Date changed from 30 Jun 2018 to 28 Jun 2019.
- 05 Mar 2018 Planned primary completion date changed from 30 Jun 2018 to 28 Jun 2019.